Erlotinib (tarceva)    (DrugBank: Erlotinib)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
94原発性硬化性胆管炎1

94. 原発性硬化性胆管炎 [臨床試験数:134,薬物数:105(DrugBank:37),標的遺伝子数:18,標的パスウェイ数:131
Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 134 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00955149
(ClinicalTrials.gov)
August 20095/8/2009Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7Primary Sclerosing Cholangitis;Trisomy 7;Cholangiocarcinoma;ChemopreventionDrug: Erlotinib (Tarceva)Mayo ClinicGenentech, Inc.Completed18 YearsN/ABoth6Phase 1United States